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ABSTRACT  
 
Background.  Internal mammary artery (IMA) grafts have better patency than vein 
grafts, but their effects on long-term clinical outcomes after coronary bypass surgery  
have been evaluated in only a few studies. 
 
Methods and Results.  We analyzed clinical outcomes over a median follow-up of 
5.9 years among 3,087 patients who received coronary bypass surgery as 
participants in one of eight clinical trials comparing surgery with angioplasty. We 
used two statistical methods (covariate adjustment and propensity score matching) 
to adjust for the non-randomized selection of IMA grafts. Both methods showed 
lower mortality associated with IMA grafting, with hazard ratios (confidence intervals) 
of 0.77 (0.62 to 0.97) for covariate adjustment and 0.77 (0.57 to 1.05) for propensity 
score matching. The composite endpoint of death or myocardial infarction was 
reduced to a similar extent, with hazard ratios of 0.83 (0.69 to 1.00) for covariate 
adjustment to  0.78 (0.61 to 1.00) for propensity score matching. There was a non-
significant trend towards less angina at one year, with odds ratios of 0.81 (0.61 to 
1.09) in the covariate adjusted model and 0.81 (0.55 to 1.19) in the propensity score 
adjusted model. 
 
Conclusion.  Use of an IMA graft during coronary bypass surgery seems to improve 
long-term clinical outcomes.  
 
Key Words:   Coronary disease, revascularization 
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 The internal mammary artery (IMA) has better long-term patency than the 
saphenous vein when used as a conduit in coronary artery bypass graft surgery 
(CABG) (1-3). While it is widely believed that this higher patency rate leads to better 
long-term clinical outcomes, there are few data to support this assumption. Only one 
randomized trial has compared use of IMA grafts with saphenous vein grafts (4). In 
that trial, patients assigned to receive an IMA graft had fewer composite endpoints of 
cardiac death, myocardial infarction, repeat revascularization and cardiac 
hospitalization over 10 years (12 of 39 versus 21 of 41, p<0.05), but did not differ 
significantly in any other endpoint. The results of this trial are not definitive because 
of its small size and because the outcome differences were driven mostly by cardiac 
hospitalizations rather than death or myocardial infarction. Observational, non-
randomized studies of between 743 and 5,931 patients who underwent CABG in the 
1970s suggest that patients who received an IMA graft had improved long-term 
survival compared with patients who received only saphenous vein grafts (5-7). 
Patients selected to receive an IMA graft, however, differed in many clinical 
characteristics from patients selected to receive only vein grafts, and these 
differences may have introduced selection bias into the comparison of outcomes that 
can be difficult to control using statistical methods. Newer approaches to the 
analysis of observational data may help control for differences between patients 
selected for different treatments (8-11), although selection biases not captured by 
measured covariates may still exist (12). The purpose of this study was to apply both 
propensity score methods and covariate adjustment methods to compare the long-
term outcomes of a more contemporary sample of patients who underwent CABG 
with or without an IMA graft. 
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Methods 
 Investigators from ten randomized trials of CABG versus percutaneous 
coronary intervention for multivessel coronary disease pooled individual patient data 
as part of a collaborative analysis of long-term treatment outcomes, as described 
previously (13). The present study is based on data from the eight trials that 
provided individual patient data on the use of IMA grafts among patients assigned to 
CABG (14-21). Use of IMA grafting in these trials was based on surgeon preference, 
and was not randomized. 
 We used multivariable logistic regression to compare baseline clinical 
characteristics of patients who received an IMA graft with those who did not. The 
results of this model were used to create a propensity score that estimated the 
probability of each patient receiving an IMA graft. For the propensity score matched 
analyses, we identified pairs of patients, one of whom received an IMA graft and one 
of whom did not, using an algorithm (22) that first paired the patients with the closest 
propensity scores, then paired the patients with the next closest propensity scores, 
etc., and stopped matching when propensity scores differed by more than 0.01. We 
required that each pair of patients be drawn from the same clinical trial, and be 
matched on the presence or absence of diabetes. 
 We assessed time-to-event for three major clinical outcomes: death; death or 
myocardial infarction; and death or myocardial infarction or repeat revascularization. 
These endpoints were defined by each trial using specific protocol definitions (14-
21).  
We used Cox proportional hazards models to analyze time-to-event 
outcomes, and logistic regression to analyze angina at one year. We performed two 
sets of analyses for each outcome. In the first set of analyses, we compared 
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outcomes of patients with and without an IMA graft among all patients, adjusting for 
patient baseline clinical characteristics (Table 1), and stratifying by trial. In the 
second set of analyses, we compared outcomes of patients with and without an IMA 
graft in the subset of patients who were matched on propensity score, adjusting for 
baseline clinical characteristics, and stratifying by trial. All statistical analyses were 
performed with R Version 2.8.1. 
 
Results 
 Data on IMA use were available for 3,087 patients who received CABG in one 
of eight clinical trials. The 2,573 patients (83%) who received an IMA graft were 
significantly less likely to be female, to have heart failure or a prior myocardial 
infarction, and significantly more likely to have proximal disease of the left anterior 
descending coronary artery or triple-vessel disease (Table 1). The use of IMA grafts 
also varied significantly by trial, ranging from 39% in GABI (17) to 96% in ERACI-II 
(16). The multivariable propensity score showed that the strongest predictor of 
whether or not a patient received an IMA graft was the trial in which the patient was 
enrolled, followed by heart failure, presence of disease in the proximal left anterior 
descending artery, female gender, and the presence of three-vessel disease (Table 
2). We were able to match on propensity score 437 of the 514 (85%) patients who 
did not receive an IMA graft with 437 patients from the same trial who did receive an 
IMA graft. As expected, the matched groups had very similar baseline characteristics 
(Table 1). 
 Among all patients receiving CABG, the unadjusted Kaplan-Meier mortality 
rate at five years was 2.6% lower among patients who received an IMA graft than 
patients who received vein grafts only, and at ten years the mortality rate was 1.9% 
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lower in the IMA group (Table 3). In a Cox model that was stratified by study and 
adjusted for all of the baseline characteristics in Table 1, use of an IMA graft was 
associated with a significantly lower risk of death, with a hazard ratio of 0.77 
(confidence interval 0.62 to 0.97, p=0.02). Use of an IMA graft was also associated 
with a significantly reduced chance of the composite endpoint of death or myocardial 
infarction and the composite endpoint of death or myocardial infarction or repeat 
revascularization (Tables 3 and 4). Angina at one year was also less frequent among 
patients who received an IMA graft, but not significantly so (Tables 3 and 4). 
 Among 437 pairs of patients matched on propensity score, study and 
diabetes, five-year mortality was 2.3% lower among patients who received an IMA 
graft than among patients who did not, and at ten years mortality was 2.5% lower in 
the IMA group (Figure 1, Table 3). In a Cox model stratified by study, use of an IMA 
graft was associated with a lower risk of death, with a hazard ratio of 0.78 
(confidence limits 0.57 to 1.05, p=0.10). The hazard ratio was essentially unchanged 
after additional adjustment for baseline characteristics (0.77, confidence limits 0.57 
to 1.05, p=0.10). There was a significantly lower incidence of the composite endpoint 
of death or MI (Figure 2, Table 3) and of the composite endpoint of death, MI, or 
repeat revascularization (Figure 3, Table 3). Angina at one year was less frequent 
among patients who received an IMA graft, but not significantly so (Tables 3 and 4). 
Discussion 
Our analysis confirms that patients who receive IMA grafts differ significantly 
from patients who receive only vein grafts in a number of prognostically important 
clinical characteristics (Table 1), including sex, a history of MI and of heart failure, 
and extent of coronary disease (Table 2). After adjusting for these and other 
differences using several different statistical methods, we found that use of an IMA 
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graft was associated with 23% lower risk of death over a 5.9 year median follow-up 
(Table 4). These results are generally consistent with the 38% risk reduction over 10 
years reported by Loop and associates (5), the 27% risk reduction over 15 years 
reported by Cameron and coworkers (6), and the 32% risk reduction over 20 years 
reported by Cameron and associates (7). The long-term risk reductions associated 
with use of IMA grafts are not as striking as the 56% to 74% reductions in procedural 
mortality reported by large clinical databases (23-26), but comparisons of 30-day 
mortality after CABG may be more susceptible to selection bias. 
 In addition to an association with lower mortality, IMA use in our study was 
also associated with lower rates of myocardial infarction, repeat revascularization, 
and angina (Tables 3 and 4). The consistency of the effect of IMA use on these 
additional endpoints is reassuring. Our results, in conjunction with earlier studies (5, 
6) suggest that the better long-term patency of the IMA graft seems to translate into 
improved long-term clinical outcomes. 
 IMA grafting has not been tested in a large, long-term clinical trial, so non-
randomized observational comparisons are the only source of information on the 
comparative effectiveness of IMA grafts and vein grafts. Patients selected for 
alternative treatments differ in a number of ways, however, so multivariable 
statistical methods have been used in an attempt to adjust for clinically important 
differences between patient groups. A variety of methods has been used (27), 
including direct adjustment for confounding factors in a multivariable model, 
propensity score adjustment and matching (8, 9), and instrumental variables 
methods (28, 29), among others. Typically, investigators choose just one of these 
methods to analyze their data, but recent studies have shown that the results of 
alternative models applied to the same dataset may well differ (30, 31). We applied 
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several approaches to the analysis of these data to evaluate whether the results 
would be affected by the choice of a statistical model. The magnitude of the effect of 
IMA on several outcome measures was quite similar whether we used direct 
adjustment for baseline covariates or propensity score matching, although the 
confidence limits were wider when sample size was reduced by matching. These 
alternative approaches may have yielded similar results in the present study 
because some adverse prognostic factors had a higher prevalence in the IMA group 
(three-vessel disease, proximal left anterior descending disease), while other 
adverse prognostic factors had a lower prevalence in the IMA group (abnormal left 
ventricular function, prior myocardial infarction). Consequently, prognosis at study 
entry may have been relatively similar in the IMA and vein graft groups due to 
offsetting imbalances in different baseline characteristics. Furthermore, all patients in 
this analysis had been selected to participate in a clinical trial, and may have had a 
narrower range of clinical characteristics than unselected patients undergoing 
CABG. The similarity in the results of alternative statistical approaches in our study 
should not be interpreted as showing these methods would yield equivalent results in 
other observational treatment comparisons. 
 This study has a number of limitations. While the data were drawn from 
clinical trials of CABG and coronary angioplasty, the use of IMA grafting was not 
randomized and varied considerably among the participating trials, and according to 
patient characteristics. We had only relatively simple clinical data available on all 
patients, so were unable to adjust for characteristics such as extent of 
atherosclerosis, and residual selection bias due to unmeasured confounders may be 
present (12). Finally, all patients underwent CABG between 1988 and 2000, and 
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may not completely reflect the results of contemporary CABG, although all were 
treated in centers with excellent cardiac surgical programs. 
 In conclusion, these data provide additional evidence that use of an IMA graft 
appears to improve long-term outcomes after CABG, and suggest that IMA use may 
be a reasonable process measure of the quality of care for CABG (32, 33). 
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           Table. 1.  Baseline Characteristics by Use of Internal Mammary Artery 
 
 
       All Patients           Matched Patients 
      No IMA         IMA         p                No IMA       IMA          p 
      (N=514)     (N=2573)                     (N=437)    (n=437) 
 
Age (mean) 61.0 60.3 0.15 60.7 60.6 0.74 
Female 30% 22% 0.0002 28% 28% 0.84 
Diabetes 17% 16% 0.82 13% 13% 1.00 
Hypertension 45% 46% 0.62 44% 47% 0.35 
Hyperlipidemia 52% 53% 0.52 51% 52% 0.61 
Current Smoker 22% 25% 0.18 23% 19% 0.11 
Proximal LAD 35% 52%  <0.0001 35% 34% 0.64 
3-Vessel Disease 29% 39%     <0.0001 29% 27% 0.49   
Unstable Angina 49% 46% 0.14 53% 52% 0.90 
Previous MI 50% 45% 0.04 49% 48% 0.70 
Heart Failure   7%   3% 0.0005   5%   4% 0.22 
Abnormal LV Function 18% 17% 0.62 19% 19% 0.80 
Peripheral Vascular  13% 11% 0.13 13% 13% 0.89 
Disease 
Study 
 ARTS   40 539    40   40 
 BARI 163 729  152 152 
 ERACI-II     9 198      9     9 
 GABI   96   62    54   54 
 MASS II   10 188    10   10 
 RITA 126 364  116 116 
 SoS   36 451    35   35   
 Toulouse   34   42    21   21  
 
IMA   = Internal mammary artery 
LAD   = Left anterior descending coronary artery 
LV  = Left ventricular 
ARTS = Arterial Revascularization Therapies Study 
BARI  = Bypass Angioplasty Revascularization Investigation 
ERACI-II = Argentine Randomized Study:  Coronary Angioplasty with  
   Stenting Versus Coronary Bypass Surgery in Multivessel Disease  
GABI  = German Angioplasty Bypass Surgery Investigation 
MASS-II = Second Medicine, Angioplasty or Surgery Study 
RITA  = Randomized Intervention Treatment of Angina 
SoS  = Stent or Surgery 
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   Table 2.  Propensity Score for Receiving an Internal Mammary Artery Graft  
 
 
   Coefficient  P-Value 
  
 Age (mean) -0.013   0.045 
 Female -0.485   0.0001 
 Diabetes  -0.072   0.63 
 Hypertension -0.092   0.42 
 Hyperlipidemia  0.014   0.92 
 Current Smoker -0.049   0.72 
 Proximal LAD  0.697 <0.0001 
 3-Vessel Disease   0.298   0.014 
 Unstable Angina -0.024   0.87 
 Previous MI -0.172   0.12 
 Heart Failure  -0.973 <0.0001 
 Abnormal LV Function -0.006   0.97 
 Peripheral Vascular Disease   0.013   0.95 
 Study   
  ARTS  Reference 
  BARI  -0.883 <0.0001 
  ERACI-II   0.458   0.24 
  GABI  -3.055 <0.0001 
  MASS-II  -0.082   0.82 
  RITA  -1.661 <0.0001 
  SoS   0.056   0.82 
  Toulouse  -2.260 <0.0001 
 Intercept   3.266 <0.0001 
  
IMA  = Internal mammary artery 
LAD  = Left anterior descending coronary artery 
LV  = Left ventricular 
ARTS = Arterial Revascularization Therapies Study 
BARI = Bypass Angioplasty Revascularization Investigation 
ERACI-II = Argentine Randomized Study:  Coronary Angioplasty with  
   Stenting Versus Coronary Bypass Surgery in Multivessel Disease  
GABI = German Angioplasty Bypass Surgery Investigation 
MASS-II = Second Medicine, Angioplasty or Surgery Study 
RITA = Randomized Intervention Treatment of Angina 
SoS = Stent or Surgery 
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        Table 3.  Incidence of Clinical Outcomes in Follow-Up by Use of the 
  Internal Mammary Artery, Based on Pooled, Unadjusted Data 
 
 
          Outcome                           All Patients            Matched Patients 
              No IMA         IMA                           No IMA         IMA           
     
          (N=514)     (N=2573)                     (N=437)       (n=437) 
 
Death (%) 
   5 years* 10.4 7.8 10.4 8.1 
   10 years* 22.5 20.6 21.7 19.2 
 
 
Death or MI (%) 
    5 years* 19.2 15.4 19.1 13.8 
   10 years* 33.3 30.4 32.2 27.6 
 
 
Death, MI or Repeat 
Revascularization (%) H 
    5 years* 20.1 14.3 19.8 16.9 
   10 years* 40.8 37.4 40.2 36.6 
 
Angina at 1 year (%) 17.8 12.8 17.8 15.4  
 
 
*   Kaplan-Meier estimates 
H   Data omits the Toulouse Study 
IMA =  Internal mammary artery 
MI  = Myocardial infarction 
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Table 4.  Comparative Outcomes:  Hazard Ratio for IMA vs. No IMA in Cox 
Models Stratified by Study  and Adjusted for Baseline Clinical Characteristics 
 
 
                      
 All Patients Matched Patients 
  (N=3087)  (N=874) 
            
  Hazard Ratio (CI) P                 Hazard Ratio (CI)    P 
 
Death   0.77 (0.62-0.97)  0.02 0.77 (0.57-1.05)      0.10 
      
       
Death/MI   0.83 (0.69-1.00)  0.05    0.78 (0.61-1.00)  0.05    
               
 
Death/MI/Repeat      0.82 (0.69-0.98)  0.03    0.85 (0.67-1.08)       0.18 
Procedure 
  
Angina* (One Year)     0.81 (0.61-1.09)  0.16              0.81 (0.55-1.19)   0.28  
 
 
 
 
 
*   Logistic regression model used to assess angina at one year. The data shown are 
odds ratios (95% confidence interval). 
 
CI   =   Confidence interval 
MI   =   Myocardial infarction 
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Figure Legends 
 
 
Figure 1. Cumulative rate of mortality (vertical axis) over ten years of follow-up 
(horizontal axis) in patients matched on propensity score. The 
outcome of patients who received an internal mammary artery (IMA) 
graft is indicated by the solid line and the survival of patients who 
received only vein grafts is indicated in the dashed line. The number of 
patients followed alive at each annual interval in each group is 
indicated below the horizontal axis. 
 
Figure 2. Cumulative rate of death or myocardial infarction over ten years of 
follow-up. Format as in Figure 1. 
 
Figure 3.  Cumulative rate of death, myocardial infarction or repeat 
revascularization over ten years of follow-up. Long-term data on 
repeat procedures were not available from the Toulouse study. Format 
as in Figure 1. 
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